Mitochondrial triglyceride transfer protein inhibition: New achievements in the treatment of dyslipidemias

Current Pharmaceutical Design

Volumn 19, Issue 17, 2013, Pages 3150-3160

  Kostapanos, Michael S ^a   Rizos, Evangelos C ^a   Papanas, Nikolaos ^b   Maltezos, Efstratios ^b   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Cardiovascular disease; Cholesterol; Fatty liver; Mitochondrial transfer protein

Indexed keywords

4' BROMO 3' METHYLMETAQUALONE; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; BILE ACID SEQUESTRANT; BMS 197636; BMS 200150; CARRIER PROTEIN; CHOLESTEROL ESTER; CHYLOMICRON; CP 10447; CP 346086; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMPLITAPIDE; JTT 130; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOCHONDRIAL TRIGLYCERIDE TRANSFER PROTEIN; MITOCHONDRIAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; NARINGENIN; NARINGENIN 7 O CETYL ETHER; PHOSPHOLIPID; SLX 4090; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DEFECATION DISORDER; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SPECIFICITY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FATTY LIVER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INDIGESTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR TRANSPORT; LIPID TRANSPORT; LOW DRUG DOSE; NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; POSTPRANDIAL LIPEMIA; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SIDE EFFECT; STEATORRHEA; TISSUE SPECIFICITY; WEIGHT REDUCTION;

ANIMALS; APOLIPOPROTEINS B; BENZAMIDES; BENZIMIDAZOLES; CARRIER PROTEINS; DYSLIPIDEMIAS; FLAVANONES; HUMANS; HYPOLIPIDEMIC AGENTS; MALONATES; METHAQUALONE;

EID: 84878646607     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319170023     Document Type: Article

References (141)

1. Allender S SP, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European cardiovascular disease statistics. European Heart Network 2008.
2. Catapano AL, Chapman J, Wiklund O, Taskinen MR. The new joint EAS/ESC guidelines for the management of dyslipidaemias. Atherosclerosis 2011; 217: 1.
3. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
4. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
5. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010; 209: 189-94.
6. Kostapanos MS, Athyros VG, Karagiannis A, Mikhailidis DP. Therapeutic options for statin-intolerant patients. Curr Med Res Opin 2012; 28: 345-9.
7. Kostapanos MS, Elisaf MS, Mikhailidis DP. Targeting cardiovascular risk: the impact of age, gender and compliance to treatment. Curr Med Res Opin 2012; 28: 1415-9.
8. Liberopoulos EN, Florentin M, Mikhailidis DP, Elisaf MS. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf 2008; 7: 717-25.
9. Daskalopoulou SS, Delaney JA, Filion KB, et al. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008; 29: 2083-91.
10. Daskalopoulou SS, Doonan RJ, Delaney JA, Pilote L. Different Patterns of Statin Use in Patients with Acute Myocardial Infarction. Curr Vasc Pharmacol 2012.
11. Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation: an underestimated risk? Curr Med Res Opin 2008; 24: 3059-62.
12. Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des 2009; 15: 490-516.
13. Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007; 23: 1169-76.
14. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Curr Med Res Opin 2008; 24: 995-1009.
15. Banegas JR, Lopez-Garcia E, Dallongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011; 32: 2143-52.
16. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5.
17. Kostapanos MS, Katsiki N, Elisaf MS, Mikhailidis DP. Editorial: reducing cardiovascular risk: is low-density lipoprotein-cholesterol (LDL-C) lowering enough? Curr Vasc Pharmacol 2012; 10: 173-7.
18. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345-61.
19. Nordestgaard BG, Stender S, Kjeldsen K. Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall. Arteriosclerosis 1988; 8: 421-8.
20. Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994; 14: 1767-74.
21. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9: 531-2.
22. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9: 533-71.
23. Zheng XY, Liu L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J Lipid Res 2007; 48: 1673-80.
24. Giannattasio C, Zoppo A, Gentile G, et al. Acute effect of high-fat meal on endothelial function in moderately dyslipidemic subjects. Arterioscler Thromb Vasc Biol 2005; 25: 406-10.
25. Suh S, Park HD, Kim SW, et al. Smaller Mean LDL Particle Size and Higher Proportion of Small Dense LDL in Korean Type 2 Diabetic Patients. Diabetes Metab J 2011; 35: 536-42.
26. Gazi I, Tsimihodimos V, Filippatos T, et al. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 2006; 55: 885-91.
27. Gazi IF, Filippatos TD, Tsimihodimos V, et al. The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids 2006; 41: 647-54.
28. Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J 2011; 5: 41-8.
29. Lopez-Ruiz A, Jarabo MM, Martinez-Triguero ML, et al. Small and dense LDL in familial combined hyperlipidemia and N291S polymorphism of the lipoprotein lipase gene. Lipids Health Dis 2009; 8: 12.
30. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152-60.
31. Kostapanos MS, Milionis HJ, Filippatos TD, et al. Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. J Cardiovasc Pharmacol Ther 2009; 14: 5-13.
32. Asztalos BF, Horvath KV, McNamara JR, et al. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002; 164: 361-9.
33. Kostapanos MS, Milionis HJ, Filippatos TD, et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther 2007; 29: 1403-14.
34. Kostapanos MS, Milionis HJ, Lagos KG, et al. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol 2008; 590: 327-32.
35. Aggarwal S, Loomba RS, Arora RR. Efficacy of colesevelam on lowering glycemia and lipids. J Cardiovasc Pharmacol 2012; 59: 198-205.
36. Kostapanos MS, Elisaf MS, Mikhailidis DP. Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipidemia. J Cardiovasc Pharmacol Ther 2012; 17: 427.
37. Kei A, Elisaf MS. Nicotinic acid: clinical considerations. Expert Opin Drug Saf 2012; 11: 551-64.
38. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007; 193: 428-37.
39. Agouridis AP, Kostapanos MS, Tsimihodimos V, et al. Effect of rosuvastatin monotherapy or in combination with fenofibrate or omega-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int J Clin Pract 2012; 66: 843-53.
40. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-61.
41. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67.
42. Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012; 308: 1024-33.
43. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Emerging options in the treatment of dyslipidemias: a bright future? Expert Opin Emerg Drugs 2011; 16: 247-70.
44. Durington PN. Hyperlipidaemia. Oxford: Health Press 2000.
45. Greeve J. Inhibition of the synthesis of apolipoprotein B-containing lipoproteins. Handb Exp Pharmacol 2005: 483-517.
46. Davis RA. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim Biophys Acta 1999; 1440: 1-31.
47. Segrest JP, Jones MK, Mishra VK, et al. apoB-100 has a pentapartite structure composed of three amphipathic alpha-helical domains alternating with two amphipathic beta-strand domains. Detection by the computer program LOCATE. Arterioscler Thromb 1994; 14: 1674-85.
48. Spring DJ, Chen-Liu LW, Chatterton JE, et al. Lipoprotein assembly. Apolipoprotein B size determines lipoprotein core circumference. J Biol Chem 1992; 267: 14839-45.
49. Gordon DA, Jamil H. Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochim Biophys Acta 2000; 1486: 72-83.
50. Borradaile NM, de Dreu LE, Barrett PH, Huff MW. Inhibition of hepatocyte apoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters. J Lipid Res 2002; 43: 1544-54.
51. Olofsson SO, Asp L, Boren J. The assembly and secretion of apolipoprotein B-containing lipoproteins. Curr Opin Lipidol 1999; 10: 341-6.
52. Chen E, Lapko VN, Lewis JW, et al. Mechanism of native oat phytochrome photoreversion: a time-resolved absorption investigation. Biochemistry 1996; 35: 843-50.
53. Fisher EA, Pan M, Chen X, et al. The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J Biol Chem 2001; 276: 27855-63.
54. Chan L. Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins. J Biol Chem 1992; 267: 25621-4.
55. Wang S, McLeod RS, Gordon DA, Yao Z. The microsomal triglyceride transfer protein facilitates assembly and secretion of apolipoprotein B-containing lipoproteins and decreases cotranslational degradation of apolipoprotein B in transfected COS-7 cells. J Biol Chem 1996; 271: 14124-33.
56. Hussain MM, Rava P, Walsh M, et al. Multiple functions of microsomal triglyceride transfer protein. Nutr Metab (Lond) 2012; 9: 14.
57. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 2003; 44: 22-32.
58. Hussain MM, Iqbal J, Anwar K, et al. Microsomal triglyceride transfer protein: a multifunctional protein. Front Biosci 2003; 8: s500-6.
59. Davidson NO, Shelness GS. APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 2000; 20: 169-93.
60. Segrest JP, Jones MK, De Loof H, Dashti N. Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 2001; 42: 1346-67.
61. Lackner KJ, Monge JC, Gregg RE, et al. Analysis of the apolipoprotein B gene and messenger ribonucleic acid in abetalipoproteinemia. J Clin Invest 1986; 78: 1707-12.
62. Slight I, Bendayan M, Malo C, et al. Identification of microsomal triglyceride transfer protein in intestinal brush-border membrane. Exp Cell Res 2004; 300: 11-22.
63. Wetterau JR, Combs KA, Spinner SN, Joiner BJ. Protein disulfide isomerase is a component of the microsomal triglyceride transfer protein complex. J Biol Chem 1990; 265: 9800-7.
64. Wang L, Fast DG, Attie AD. The enzymatic and non-enzymatic roles of protein-disulfide isomerase in apolipoprotein B secretion. J Biol Chem 1997; 272: 27644-51.
65. Wetterau JR, Combs KA, McLean LR, et al. Protein disulfide isomerase appears necessary to maintain the catalytically active structure of the microsomal triglyceride transfer protein. Biochemistry 1991; 30: 9728-35.
66. Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, Wetterau JR. The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Annu Rev Nutr 2000; 20: 663-97.
67. Rava P, Athar H, Johnson C, Hussain MM. Transfer of cholesteryl esters and phospholipids as well as net deposition by microsomal triglyceride transfer protein. J Lipid Res 2005; 46: 1779-85.
68. Wang Y, Tran K, Yao Z. The activity of microsomal triglyceride transfer protein is essential for accumulation of triglyceride within microsomes in McA-RH7777 cells. A unified model for the assembly of very low density lipoproteins. J Biol Chem 1999; 274: 27793-800.
69. Rustaeus S, Stillemark P, Lindberg K, et al. The microsomal triglyceride transfer protein catalyzes the post-translational assembly of apolipoprotein B-100 very low density lipoprotein in McA-RH7777 cells. J Biol Chem 1998; 273: 5196-203.
70. Gordon DA, Jamil H, Gregg RE, et al. Inhibition of the microsomal triglyceride transfer protein blocks the first step of apolipoprotein B lipoprotein assembly but not the addition of bulk core lipids in the second step. J Biol Chem 1996; 271: 33047-53.
71. Atzel A, Wetterau JR. Mechanism of microsomal triglyceride transfer protein catalyzed lipid transport. Biochemistry 1993; 32: 10444-50.
72. Atzel A, Wetterau JR. Identification of two classes of lipid molecule binding sites on the microsomal triglyceride transfer protein. Biochemistry 1994; 33: 15382-8.
73. Jamil H, Dickson JK, Jr., Chu CH, et al. Microsomal triglyceride transfer protein. Specificity of lipid binding and transport. J Biol Chem 1995; 270: 6549-54.
74. Hussain MM, Bakillah A, Jamil H. Apolipoprotein B binding to microsomal triglyceride transfer protein decreases with increases in length and lipidation: implications in lipoprotein biosynthesis. Biochemistry 1997; 36: 13060-7.
75. Bakillah A, Nayak N, Saxena U, et al. Decreased secretion of ApoB follows inhibition of ApoB-MTP binding by a novel antagonist. Biochemistry 2000; 39: 4892-9.
76. Gordon DA, Jamil H, Sharp D, et al. Secretion of apolipoprotein Bcontaining lipoproteins from HeLa cells is dependent on expression of the microsomal triglyceride transfer protein and is regulated by lipid availability. Proc Natl Acad Sci U S A 1994; 91: 7628-32.
77. Leiper JM, Bayliss JD, Pease RJ, et al. Microsomal triglyceride transfer protein, the abetalipoproteinemia gene product, mediates the secretion of apolipoprotein B-containing lipoproteins from heterologous cells. J Biol Chem 1994; 269: 21951-4.
78. Herscovitz H, Kritis A, Talianidis I, et al. Murine mammaryderived cells secrete the N-terminal 41% of human apolipoprotein B on high density lipoprotein-sized lipoproteins containing a triacylglycerol-rich core. Proc Natl Acad Sci U S A 1995; 92: 659-63.
79. Rusinol AE, Jamil H, Vance JE. In vitro reconstitution of assembly of apolipoprotein B48-containing lipoproteins. J Biol Chem 1997; 272: 8019-25.
80. Macri J, Kazemian P, Kulinski A, et al. Translocational status of ApoB in the presence of an inhibitor of microsomal triglyceride transfer protein. Biochem Biophys Res Commun 2000; 276: 1035-47.
81. Lin MC, Gordon D, Wetterau JR. Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res 1995; 36: 1073-81.
82. Au WS, Kung HF, Lin MC. Regulation of microsomal triglyceride transfer protein gene by insulin in HepG2 cells: roles of MAPKerk and MAPKp38. Diabetes 2003; 52: 1073-80.
83. Jin UH, Kang YJ, Chang YC, Kim CH. Secretion of atherogenic risk factor apolipoprotein B-100 is increased by a potential mechanism of JNK/PKC-mediated insulin resistance in liver cells. J Cell Biochem 2008; 103: 908-19.
84. Lally S, Tan CY, Owens D, Tomkin GH. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 2006; 49: 1008-16.
85. Qin B, Qiu W, Avramoglu RK, Adeli K. Tumor necrosis factoralpha induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein B48-containing lipoproteins. Diabetes 2007; 56: 450-61.
86. Qin B, Anderson RA, Adeli K. Tumor necrosis factor-alpha directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling. Am J Physiol Gastrointest Liver Physiol 2008; 294: G1120-9.
87. Benoist F, Grand-Perret T. Co-translational degradation of apolipoprotein B100 by the proteasome is prevented by microsomal triglyceride transfer protein. Synchronized translation studies on HepG2 cells treated with an inhibitor of microsomal triglyceride transfer protein. J Biol Chem 1997; 272: 20435-42.
88. Aggarwal D, West KL, Zern TL, et al. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord 2005; 5: 30.
89. Barter P. CETP and atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2029-31.
90. Allister EM, Borradaile NM, Edwards JY, Huff MW. Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. Diabetes 2005; 54: 1676-83.
91. Borradaile NM, de Dreu LE, Barrett PH, et al. Hepatocyte apoBcontaining lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation. Biochemistry 2003; 42: 1283-91.
92. Wilcox LJ, Borradaile NM, de Dreu LE, Huff MW. Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. J Lipid Res 2001; 42: 725-34.
93. Borradaile NM, Carroll KK, Kurowska EM. Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavanones hesperetin and naringenin. Lipids 1999; 34: 591-8.
94. Shin YW, Bok SH, Jeong TS, et al. Hypocholesterolemic effect of naringin associated with hepatic cholesterol regulating enzyme changes in rats. Int J Vitam Nutr Res 1999; 69: 341-7.
95. Lee MK, Moon SS, Lee SE, et al. Naringenin 7-O-cetyl ether as inhibitor of HMG-CoA reductase and modulator of plasma and hepatic lipids in high cholesterol-fed rats. Bioorg Med Chem 2003; 11: 393-8.
96. Lee SH, Park YB, Bae KH, et al. Cholesterol-lowering activity of naringenin via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A:cholesterol acyltransferase in rats. Ann Nutr Metab 1999; 43: 173-80.
97. Lee CH, Jeong TS, Choi YK, et al. Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits. Biochem Biophys Res Commun 2001; 284: 681-8.
98. Bok SH, Lee SH, Park YB, et al. Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl-CoA reductase and acyl CoA: cholesterol transferase are lower in rats fed citrus peel extract or a mixture of citrus bioflavonoids. J Nutr 1999; 129: 1182-5.
99. Borradaile NM, de Dreu LE, Huff MW. Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation. Diabetes 2003; 52: 2554-61.
100. Choi JS, Yokozawa T, Oura H. Improvement of hyperglycemia and hyperlipemia in streptozotocin-diabetic rats by a methanolic extract of Prunus davidiana stems and its main component, prunin. Planta Med 1991; 57: 208-11.
101. Mulvihill EE, Assini JM, Sutherland BG, et al. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol 2010; 30: 742-8.
102. Benoist F, Nicodeme E, Grand-Perret T. Microsomal triacylglycerol transfer protein prevents presecretory degradation of apolipoprotein B-100. A dithiothreitol-sensitive protease is involved. Eur J Biochem 1996; 240: 713-20.
103. Nicodeme E, Benoist F, McLeod R, et al. Identification of domains in apolipoprotein B100 that confer a high requirement for the microsomal triglyceride transfer protein. J Biol Chem 1999; 274: 1986-93.
104. Kulinski A, Rustaeus S, Vance JE. Microsomal triacylglycerol transfer protein is required for lumenal accretion of triacylglycerol not associated with ApoB, as well as for ApoB lipidation. J Biol Chem 2002; 277: 31516-25.
105. Dashti N, Manchekar M, Liu Y, et al. Microsomal triglyceride transfer protein activity is not required for the initiation of apolipoprotein B-containing lipoprotein assembly in McA-RH7777 cells. J Biol Chem 2007; 282: 28597-608.
106. Lomitapide. Am J Cardiovasc Drugs 2011; 11: 347-52.
107. Funatsu T, Suzuki K, Goto M, et al. Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Atherosclerosis 2001; 157: 107-15.
108. Dhote V, Joharapurkar A, Kshirsagar S, et al. Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats. Clin Exp Pharmacol Physiol 2011; 38: 338-44.
109. Funatsu T, Kakuta H, Takasu T, Miyata K. Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor. Eur J Pharmacol 2002; 455: 161-7.
110. Shiomi M, Ito T. MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur J Pharmacol 2001; 431: 127-31.
111. Frankel HL. Associated chest injuries. Paraplegia 1968; 5: 221-5.
112. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9: 258-70.
113. Burnett JR. Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia. IDrugs 2006; 9: 495-9.
114. Mera Y, Odani N, Kawai T, et al. Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]p henyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an intestinespecific inhibitor of microsomal triglyceride transfer protein. J Pharmacol Exp Ther 2011; 336: 321-7.
115. Conde K, Pineda G, Newton RS, Fernandez ML. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin. Biochem Pharmacol 1999; 58: 1209-19.
116. Hata T, Mera Y, Ishii Y, et al. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner. J Pharmacol Exp Ther 2011; 336: 850-6.
117. Hata T, Mera Y, Tadaki H, et al. JTT-130, a novel intestinespecific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet-induced obesity and glucose intolerance in Sprague-Dawley rats. Diabetes Obes Metab 2011; 13: 446-54.
118. D'Alessio DA, Sandoval DA, Seeley RJ. New ways in which GLP-1 can regulate glucose homeostasis. J Clin Invest 2005; 115: 3406-8.
119. Executive summary: Standards of medical care in diabetes--2012. Diabetes Care 2012; 35 Suppl 1: S4-S10.
120. Hata T, Mera Y, Kawai T, et al. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates impaired glucose and lipid metabolism in Zucker diabetic fatty rats. Diabetes Obes Metab 2011; 13: 629-38.
121. Kim E, Campbell S, Schueller O, et al. A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther 2011; 337: 775-85.
122. Haghpassand M, Wilder D, Moberly JB. Inhibition of apolipoprotein B and triglyceride secretion in human hepatoma cells (HepG2). J Lipid Res 1996; 37: 1468-80.
123. Pan M, Liang J, Fisher EA, Ginsberg HN. Inhibition of translocation of nascent apolipoprotein B across the endoplasmic reticulum membrane is associated with selective inhibition of the synthesis of apolipoprotein B. J Biol Chem 2000; 275: 27399-405.
124. Jamil H, Gordon DA, Eustice DC, et al. An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Proc Natl Acad Sci U S A 1996; 93: 11991-5.
125. Hebbachi A, Gibbons GF. Inactivation of microsomal triglyceride transfer protein impairs the normal redistribution but not the turnover of newly synthesized glycerolipid in the cytosol, endoplasmic reticulum and Golgi of primary rat hepatocytes. Biochim Biophys Acta 1999; 1441: 36-50.
126. Hebbachi AM, Brown AM, Gibbons GF. Suppression of cytosolic triacylglycerol recruitment for very low density lipoprotein assembly by inactivation of microsomal triglyceride transfer protein results in a delayed removal of apoB-48 and apoB-100 from microsomal and Golgi membranes of primary rat hepatocytes. J Lipid Res 1999; 40: 1758-68.
127. van Greevenbroek MM, Robertus-Teunissen MG, Erkelens DW, de Bruin TW. Participation of the microsomal triglyceride transfer protein in lipoprotein assembly in Caco-2 cells: interaction with saturated and unsaturated dietary fatty acids. J Lipid Res 1998; 39: 173-85.
128. Chandler CE, Wilder DE, Pettini JL, et al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003; 44: 1887-901.
129. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356: 148-56.
130. Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008; 5: 497-505.
131. Rizzo M. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. IDrugs 2010; 13: 103-11.
132. Ueshima K, Akihisa-Umeno H, Nagayoshi A, et al. Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull 2005; 28: 247-52.
133. Ksander GM, deJesus R, Yuan A, et al. Diaminoindanes as microsomal triglyceride transfer protein inhibitors. J Med Chem 2001; 44: 4677-87.
134. Bjorkegren J, Beigneux A, Bergo MO, et al. Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury. J Biol Chem 2002; 277: 5476-83.
135. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011; 9: 698-705.
136. Mikhailidis DP, Lioudaki E, Ganotakis ES. Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des 2011; 17: 3632-43.
137. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
138. Spann NJ, Kang S, Li AC, et al. Coordinate transcriptional repression of liver fatty acid-binding protein and microsomal triglyceride transfer protein blocks hepatic very low density lipoprotein secretion without hepatosteatosis. J Biol Chem 2006; 281: 33066-77.
139. Vu CB, Milne JC, Carney DP, et al. Discovery of benzothiazole derivatives as efficacious and enterocyte-specific MTP inhibitors. Bioorg Med Chem Lett 2009; 19: 1416-20.
140. Rizzo M, Wierzbicki AS. New lipid modulating drugs: the role of microsomal transport protein inhibitors. Curr Pharm Des 2011; 17: 943-9.
141. Filippatos TD, Derdemezis CS, Gazi IF, et al. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31: 53-65.